v3.26.1
Acquisitions and Licensing Agreements - Additional Information (Details)
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
May 01, 2026
USD ($)
Sep. 04, 2025
USD ($)
shares
Feb. 24, 2025
USD ($)
Employees
Jun. 07, 2024
USD ($)
Jun. 06, 2024
USD ($)
Jun. 02, 2021
USD ($)
Sep. 30, 2025
USD ($)
Nov. 30, 2024
USD ($)
$ / shares
shares
Jun. 30, 2026
USD ($)
shares
Jun. 30, 2025
USD ($)
Jun. 30, 2026
USD ($)
shares
Jun. 30, 2025
USD ($)
Dec. 31, 2024
USD ($)
Dec. 31, 2025
USD ($)
shares
Business Combination [Line Items]                            
Compensation expense                 $ 11,695,000 $ 18,651,000 $ 17,053,000 $ 21,589,000    
Bargain purchase gain                 0 0 0 5,232,000    
Income tax benefit                 0 0 0 4,167,000    
Amortization expense related to finite-lived intangible assets                 1,100,000 1,000,000 2,200,000 1,300,000    
Contingent consideration milestone probability of achieving within 12 months                 $ 26,066,000   $ 26,066,000     $ 2,500,000
Preferred stock, shares issued | shares                 0   0     0
Research and development                 $ 56,365,000 35,839,000 $ 101,432,000 54,613,000    
Location, Statement of Income, Balance [Axis]: us-gaap:GeneralAndAdministrativeExpense                            
Business Combination [Line Items]                            
Compensation expense                 8,261,000 14,046,000 11,287,000 15,748,000    
Location, Statement of Income, Balance [Axis]: us-gaap:ResearchAndDevelopmentExpense                            
Business Combination [Line Items]                            
Compensation expense                 3,434,000 4,605,000 5,766,000 5,841,000    
Prolaio, Inc.                            
Business Combination [Line Items]                            
Percentage of outstanding shares acquired     100.00%                      
Purchase consideration transferred     $ 8,600,000                      
Cash consideration     4,000,000                      
Fair value of contingent milestone $ 13,700,000   4,600,000           47,300,000   47,300,000     $ 3,800,000
Acquisition related costs     800,000                   $ 1,000,000  
Net assets acquired     13,812,000                      
Liabilities assumed     13,823,000                      
Deferred income tax liability     4,512,000                      
Assumed contingent consideration liability     $ 3,300,000                      
Bargain purchase gain                       5,200,000 5,200,000  
Income tax benefit                         4,200,000  
Incremental stock-based compensation expense related to accelerated vesting of options upon acquisition                   14,400,000   14,400,000 1,600,000  
Pro forma revenue                   0 0      
Discounted rate of milestones required to be achieved     10.00%                      
Milestones achieved                 0   0      
Change in fair value of contingent consideration liability                 43,500,000 0 43,500,000 0    
Milestone payments                     0      
Cash and cash equivalents     $ 14,000                      
Accounts payable     2,710,000                      
PhysIQ, Inc.                            
Business Combination [Line Items]                            
Fair value of contingent milestone     $ 3,300,000           3,900,000   3,900,000     3,900,000
Business combination, contingent milestone payments                 0   0      
Acquisition related costs                 0 0        
Discounted rate of milestones required to be achieved     10.00%                      
Contingent consideration milestone probability of achieving within 12 months                           2,500,000
RSF                            
Business Combination [Line Items]                            
Percentage of outstanding shares acquired         100.00%                  
Purchase consideration transferred         $ 14,800,000                  
Cash consideration         3,500,000                  
Business combination, contingent milestone payments                 0   0      
Milestones achieved                 0   0      
Cash and cash equivalents         200,000                  
Accounts payable         1,300,000                  
Milestone payment obligation             $ 3,000,000              
Milestone payment settled in cash             $ 1,500,000              
In-process research and development asset         15,900,000                  
Payment of transaction costs         700,000                  
Settlement of outstanding indebtedness         10,600,000                  
Mr. Gianakakos | Prolaio, Inc.                            
Business Combination [Line Items]                            
Related party transaction, beneficial ownership percentage     55.70%                      
Repayment of promissory notes     $ 4,000,000                      
Mr. Gianakakos | Milestone One | Prolaio, Inc.                            
Business Combination [Line Items]                            
Milestone payments received 12,900,000                          
Mr. Gianakakos | Milestone Two | Prolaio, Inc.                            
Business Combination [Line Items]                            
Milestone payments received 31,300,000                          
Mr. Gianakakos | Milestone Three | Prolaio, Inc.                            
Business Combination [Line Items]                            
Milestone payments received 62,400,000                          
Dr. Edelberg | Prolaio, Inc.                            
Business Combination [Line Items]                            
Related party transaction, beneficial ownership percentage     17.10%                      
Dr. Edelberg | Milestone One | Prolaio, Inc.                            
Business Combination [Line Items]                            
Milestone payments received 3,600,000                          
Dr. Edelberg | Milestone Two | Prolaio, Inc.                            
Business Combination [Line Items]                            
Milestone payments received 9,800,000                          
Dr. Edelberg | Milestone Three | Prolaio, Inc.                            
Business Combination [Line Items]                            
Milestone payments received 19,500,000                          
Minimum | Prolaio, Inc.                            
Business Combination [Line Items]                            
Milestone payments 5,000,000,000                          
Minimum | Mr. Gianakakos | Prolaio, Inc.                            
Business Combination [Line Items]                            
Milestone payments 6,000,000,000                          
Minimum | Dr. Edelberg | Prolaio, Inc.                            
Business Combination [Line Items]                            
Milestone payments 12,000,000,000                          
Maximum | Prolaio, Inc.                            
Business Combination [Line Items]                            
Business combination, contingent milestone payments     $ 200,000,000                      
Number of years milestones required to be achieved     4 years                      
Milestone payments 50,000,000                          
Maximum | PhysIQ, Inc.                            
Business Combination [Line Items]                            
Business combination, contingent milestone payments     $ 20,000,000                      
Number of years milestones required to be achieved     4 years                      
Maximum | RSF                            
Business Combination [Line Items]                            
Development and regulatory milestone payments         26,500,000                  
Sales milestones payments         $ 249,500,000                  
Maximum | Mr. Gianakakos | Prolaio, Inc.                            
Business Combination [Line Items]                            
Milestone payments 50,000,000                          
Milestone payments received 106,600,000                          
Maximum | Dr. Edelberg | Prolaio, Inc.                            
Business Combination [Line Items]                            
Milestone payments 100,000,000                          
Milestone payments received $ 32,900,000                          
Developed Technology | Prolaio, Inc.                            
Business Combination [Line Items]                            
Finite-lived intangibles     $ 25,400,000                      
Amortization expense related to finite-lived intangible assets                       600,000    
Estimated number of years to recreate technology     3 years 8 months 12 days                      
Estimated number of employees to recreate technology | Employees     50                      
Developed Technology | Minimum | Prolaio, Inc.                            
Business Combination [Line Items]                            
Estimated average annual cost per employee to recreate technology     $ 100,000                      
Developed Technology | Maximum | Prolaio, Inc.                            
Business Combination [Line Items]                            
Estimated average annual cost per employee to recreate technology     200,000                      
In-process Research and Development | Prolaio, Inc.                            
Business Combination [Line Items]                            
Finite-lived intangibles     1,100,000                      
Bonus Agreements [Member] | Prolaio, Inc.                            
Business Combination [Line Items]                            
Compensation expense                 0   0      
Bonus Agreements [Member] | Prolaio, Inc. | Location, Statement of Income, Balance [Axis]: us-gaap:GeneralAndAdministrativeExpense                            
Business Combination [Line Items]                            
Compensation expense                   11,700,000   11,700,000    
Bonus Agreements [Member] | Prolaio, Inc. | Location, Statement of Income, Balance [Axis]: us-gaap:ResearchAndDevelopmentExpense                            
Business Combination [Line Items]                            
Compensation expense                   $ 2,600,000   $ 2,600,000    
Bonus Agreements [Member] | Mr. Gianakakos | Prolaio, Inc.                            
Business Combination [Line Items]                            
Business combination, contingent bonus amount     9,000,000                      
Bonus Agreements [Member] | Dr. Edelberg | Prolaio, Inc.                            
Business Combination [Line Items]                            
Business combination, contingent bonus amount     $ 2,000,000                      
License Agreement With Sanofi [Member] | RSF                            
Business Combination [Line Items]                            
Milestones achieved                 0   0      
Milestone payments                     0      
Commercial milestone payments           $ 14,800,000                
License Agreement With Mayo [Member] | RSF                            
Business Combination [Line Items]                            
Milestones achieved                 0   0      
Milestone payments                     0      
Development and regulatory milestone payments           300,000                
Commercial milestone payments           $ 1,300,000                
Ionis License Agreement [Member]                            
Business Combination [Line Items]                            
Milestone payments       $ 375,000,000                    
Upfront payment       20,000,000                 20,000,000  
Development and regulatory milestone payments       35,000,000                    
Sales milestones payments       $ 340,000,000                    
License Agreements with MyoKardia and BMS Co. [Member]                            
Business Combination [Line Items]                            
Milestones achieved                 0   0      
Milestone payments                     0      
Fair value of shares per share | $ / shares               $ 19.1            
Fair value of shares               $ 29,500,000            
Research and development                         $ 29,500,000  
License Agreements with MyoKardia and BMS Co. Related to Dani Agreement [Member] | Maximum                            
Business Combination [Line Items]                            
Development and regulatory milestone payments               42,500,000            
Sales milestones payments               265,000,000            
License Agreements with MyoKardia and BMS Co. Related to Par4 Agreement [Member]                            
Business Combination [Line Items]                            
Development and regulatory milestone payments, tranche one               12,500,000            
Development and regulatory milestone payments, tranche two               13,625,000            
Sales milestones payments               265,000,000            
License Agreements with MyoKardia and BMS Co. Related to Par4 Agreement [Member] | Maximum                            
Business Combination [Line Items]                            
Development and regulatory milestone payments               $ 10,000,000            
Series B Preferred Stock | Bonus Agreements [Member] | Prolaio, Inc.                            
Business Combination [Line Items]                            
Business combination, consideration transferred, equity interest, number of shares issued | shares   374,360                        
Business combination, consideration transferred, equity interest, value of shares issued   $ 8,000,000                        
Bonus shares, cash remitted to satisfy related tax obligations   $ 6,400,000                        
Series A Preferred Stock                            
Business Combination [Line Items]                            
Fair value of shares per share | $ / shares               $ 19.1            
Fair value of shares               $ 29,500,000            
Series A Preferred Stock | License Agreements with MyoKardia and BMS Co. [Member]                            
Business Combination [Line Items]                            
Preferred stock, shares issued | shares               1,544,576            
Series A Preferred Stock | License Agreements with MyoKardia and BMS Co. Related to Dani Agreement [Member]                            
Business Combination [Line Items]                            
Preferred stock, shares issued | shares               1,251,107            
Series A Preferred Stock | License Agreements with MyoKardia and BMS Co. Related to Par4 Agreement [Member]                            
Business Combination [Line Items]                            
Preferred stock, shares issued | shares               293,469            
Accrued and Other Current Liabilities [Member] | RSF                            
Business Combination [Line Items]                            
Milestone payment accrued                 $ 1,500,000   $ 1,500,000     $ 1,500,000